[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644691":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":39,"collaborators":42,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Hospital Garcia de Orta","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Ambulatory patients referred to percutaneous endoscopic gastrostomy for long-term enteral nutrition.",null,"Adult patients (age above 18 years) with oral ingestion below 50% of energy daily needs for a minimum period of 1 month and absence of any form of artificial nutrition (oral supplements, tube feeding or parenteral nutrition) before percutaneous endoscopic gastrostomy.",[13],{"name":14,"affiliation":15,"role":16},"Gonçalo Nunes, MD","Gastroenterology Department, GENE - Artificial Feeding Team, Unidade Local de Saúde Almada-Seixal, Hospital Garcia de Orta, Almada, Portugal.","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Gonçalo Nunes, MD, MSc","CONTACT","00351965492185","goncalo.n@hotmail.com",{"name":24,"role":20,"phone":10,"phoneExt":10,"email":25},"Jorge Fonseca, MD, MSc, PhD","jorgedafonseca@gmail.com",[27],{"facility":5,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"Almada","Setúbal District","2670-487","Portugal","PT",{"type":34,"coordinates":35},"Point",[36,37],-9.1569,38.67902,{"lat":37,"lon":36},{"type":16,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Gonçalo Filipe Domingos Nunes","Medical Doctor",[43],{"name":44,"class":6},"Instituto de Ciências Biomédicas Abel Salazar","100644691","gastrointestinal-hormones-and-metabolomic-profiling-following-mixed-meal-tolerance-tests-in-patients-at-risk-of-refeeding-syndrome-100644691",false,"NCT07674589","Gastrointestinal Hormones and Metabolomic Profiling Following Mixed-Meal Tolerance Tests in Patients at Risk of Refeeding Syndrome","Combined Assessment of Gastrointestinal Hormones and Metabolomic Profiling Following Mixed-Meal Tolerance Tests in Patients at High Risk of Refeeding Syndrome: Study Protocol","Inclusion Criteria:\n\n* Age above 18 years.\n* Oral ingestion below 50% of energy daily needs for ≥ 1 month.\n* Absence of artificial nutrition before PEG placement.\n\nExclusion Criteria:\n\n* Age below 18 years.\n* Quantified food ingestion above 50% of energy daily needs during the last month.\n* Oncologic disease.\n* Diabetes mellitus.\n* Expected survival below 3 months.\n* Inability to provide credible anamnestic data.\n* Impossibility to have an appropriate clinical and nutritional follow-up.","ALL","18 Years",{"count":55,"type":56},15,"ESTIMATED","OBSERVATIONAL","Introduction: Refeeding syndrome (RS) is a life-threatening metabolic complication of nutritional support. Prolonged fasting, frequently observed in malnourished patients referred for percutaneous endoscopic gastrostomy (PEG), induces histological and ultrastructural changes in the intestinal mucosa, potentially influencing RS development. Mixed-Meal Tolerance Tests (MMTT) combined with metabolomics allow dynamic assessment of serum glucose, gastrointestinal hormones and cellular metabolites, which may help to elucidate RS pathogenesis and assess patient risk. Objective: The present study aims to perform MMTT in PEG-fed patients to evaluate enteroendocrine hormone responses and metabolomic profiles following a prolonged fasting period and subsequent enteral refeeding. Methods: This prospective, single-center study includes adults referred for PEG after at least one month of oral intake below 50% of energy needs. The MMTT will be performed at PEG placement and after 3-6 months of enteral nutrition. Serial blood samples will be collected from baseline up to 120 minutes post-meal to measure serum glucose, insulin, C-peptide, electrolytes and gastrointestinal hormones (GLP-1\u002FGIP\u002FGhrelin\u002FPeptide YY), and for metabolomic profiling by spectroscopy. Clinical and nutritional data will be prospectively recorded. Statistical and multivariate analyses will assess metabolic and hormonal changes over time and their potential association with patient refeeding syndrome risk and clinical outcome. The study was approved by the institutional ethics committee, and patient informed consent will be obtained. Conclusion: This study integrates MMTT and metabolomic profiling to characterize hormonal and metabolic responses during fasting and refeeding in high-risk PEG patients. Findings are expected to reveal underlying mechanisms of RS, identify potential predictive biomarkers, and improve individualized risk stratification and nutritional management.",[60,61],"Refeeding Syndrome","Malnutrition",[60,63,64,65,66],"Gastrointestinal Hormones","Metabolomics","Mixed-Meal Tolerance Tests","PEG","NOT_YET_RECRUITING","2026-06-25",{"date":70,"type":71},"2026-06-29","ACTUAL",{"date":73,"type":56},"2026-07",{"date":75,"type":56},"2027-07",{"name":5,"class":6},1]